This weekend, Sarah Cannon Research Institute will be sharing its cancer research insights through 91 presentations at the 51 st annual ASCO¨ ( American Society of Clinical Oncology ) meeting in Chicago. The meeting, held May 29 Ð June 2, is the worldÕs largest conference for cancer experts to review research data that is helping to better identify and treat various types of cancers.
ÒWe look forward to sharing our research progress at this yearÕs meeting, which includes 48 phase I abstracts and represents our collaborations with 46 pharmaceutical and biotech partners,Ó said Chief Medical Officer and Executive Director, Sarah Cannon Research Institute Drug Development Program, Howard A. Burris III, MD . ÒFrom immunotherapies to agents that target genetic mutations, we continue to gain knowledge about which therapies are helping patients more effectively fight their cancer.Ó
Presentations by Sarah Cannon Research Institute include four clinical science symposiums, 11 oral presentation sessions, 17 poster discussion sessions, 55 general posters, three educational sessions and one community-based research forum.
Highlights of Sarah Cannon Research InstituteÕs research at the ASCO¨ Annual Meeting include presentations by:
- David R. Spigel, MD, Director, Lung Cancer Research Program at Sarah Cannon Research Institute, regarding the recently approved immunotherapy drug, nivolumab in a phase III study compared against the chemotherapy drug, docetaxel for relapsed patients with advanced stage squamous cell lung cancer
- Professor Paul Ellis, MD, FRACP, Principal Investigator from Sarah Cannon Research Ð United Kingdom, presenting the primary results of the MARIANNE study which investigated three HER-2 targeted regimens in patients with previously untreated (first line) advanced HER2-positive breast cancer
- Denise A. Yardley, MD, Senior Investigator, Breast Cancer Research Program, discussing phase III TITAN clinical trial data studying combination chemotherapy treatment regimen for patients with early-stage triple-negative breast cancer
- Jesus G. Berdeja, MD, Senior Investigator and Director, Myeloma Research Program, presenting an update on a phase I/II study on the use of panobinostat in combination with carfilzomib for patients with relapsed or relapsed/refractory multiple myeloma
- Jeffrey R. Infante, MD, Principal Investigator and Director, Drug Development Program, discussing the findings on the dose escalation stage of a first-in-class phase I study testing BVD-523, a new targeted drug designed to inhibit ERK kinase, a member of a signaling pathway that can lead to tumor development
We provide live coverage from the annual ASCO meeting through our social media channels. Find Sarah Cannon on Twitter , Facebook , and LinkedIn . To stay updated on Sarah Cannon Research InstituteÕs presentations and the latest in cancer research, visit sarahcannon.com/ASCO . On the site, you can find an infographic, a full list of abstracts, the presentation schedule, along with posters and fact sheets for the meeting.